Abstracts by keywords: CGM
In Germany, around 7.5 million people live with diabetes (IDF2017) [1]. A total of 95% of them have type 2 diabetes (T2D) and 5% have diabetes type 1 (T1D) or another type according to the diabetes classification [2]. In many cases, oral antidiabetic drugs for T2D or insulin for T1D and T2D can be used very successfully [3-4]. The goal of diabetes management is always to achieve and maintain good blood sugar control. As recommended by the American Diabetes Association, a glucose level of 70-180 mg/dl (3.8-10 mmol/l) should be achieved. This value can of course be adjusted individually as required. The second goal is to avoid hypoglycemia (<70 mg/dl or <3.8 mmol/l) and hyperglycemia (>180 mg/dl or 10 mmol/l) as much as possible. The long-term goal of diabetes treatment is the prevention of diabetes complications such as retinopathy, nephropathy and neuropathy [5-10]. The biggest burden in the daily life of a patient with diabetes is monitoring blood sugar. Many fingertip blood samples are necessary every day in order to be able to adjust the individual insulin regimen and achieve good blood sugar control. In order to achieve optimal blood sugar control with intensive therapy, frequent blood sugar measurements are necessary (self-monitoring of blood sugar levels (SMBG)). Unfortunately, capillary blood sampling is not able to adequately prevent hypoglycemia and hyperglycemia. Hypoglycemia and hyperglycemia affect quality of life, and hypoglycemia in particular is a major burden in living with diabetes [11]. Blood glucose testing is very time-consuming and painful and many factors must be taken into account. In addition, capillary blood glucose measurements only represent a snapshot of the current glucose level. Flash Glucose Monitoring (FGM) has been available in Germany since 2014 and is reimbursed by health insurance companies for adults and children aged 4 and over with T1D and T2D.